ABSTRACT

Research work involves in formulation development of a modified release dosage form of Quinine sulfate mini- tablets using cellulosic polymers (Hypromellose) as a release retarding agent for reduction of dosing frequency and patient compliance. The formulation is evaluated by titrating with various concentration of Hypromellose of two different grades, HPMC K4M and HPMC K100LVCR (two different viscosity range of polymers) to achieve the target drug release of loading dose plus maintenance dose. The manufacturing process involves, wet granulation, and followed by compression. The formulation with 10% w/w of HPMC K4M and 5% w/w of K100LVCR was observed with release profile complies with zero order kinetics model. Sustained release matrix can promise better compliance through reduction in over-all dose and dosage regimen, which support to treat continual sickness. The developed formulation can improve the patient compliance and reduces the dosage regimen. Keywords: Quinine sulfate, Hypromellose, sustained release, mini-tablets
Publication date: 01/03/2025

https://ijbpas.com/pdf/2025/March/MS_IJBPAS_2025_8775.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.3.8775